The Lung Emphysema Registry: Improving quality of care in interventional emphysema therapy and health management for patients with advanced COPD and lung emphysema

被引：0

作者：

Rummenholl, Monika ^{[1
]}

Sgarbossa, Thomas ^{[2
]}

Grah, Christian ^{[3
]}

Holland, Angelique ^{[4
]}

Huebner, Ralf-Harto ^{[5
]}

机构：

[1] Lungenemphysemregister eV, Kladower Damm 221, D-14089 Berlin, Germany

[2] Charite Univ Med Berlin, Klin Pneumol Beatmungsmed & Intens Med Arbeitsbere, Berlin, Germany

[3] Gemeinschaftskrankenhaus Havelhohe gGmbH, Klin Pneumol, Berlin, Germany

[4] Univ Klinikum Giessen & Marburg Standort Marburg, Pneumol, Marburg, Germany

[5] Charite Univ Med Berlin, Med Klin mS Infektiol & Pneumol, Berlin, Germany

来源：

PNEUMOLOGIE | 2025年

关键词：

COPD; Pulmonary emphysema register; certification; research; network; ENDOBRONCHIAL VALVE TREATMENT; VOLUME-REDUCTION; NATIONAL EMPHYSEMA; FOLLOW-UP; FISSURES; UPDATE;

D O I：

10.1055/a-2532-4885

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

The Lungenemphysemregister e.V. (LE-Register) offers a specialized platform for the exchange of knowledge, the promotion of research and the improvement of the quality of care in interventional endoscopic and surgical therapies as well as the consideration of other socio-economic and health aspects of pulmonary emphysema. The current focus is primarily on endoscopic and surgical treatment approaches for patients. Through the networking of experts, the development of specific quality standards and the certification of centers, the LE Registry contributes to the evidence-based further development and optimization of these highly specialized therapies and with a focus on other aspects of health promotion in the future.

引用

页数：6

共 37 条

[1] Rabe K.F., Watz H., Chronic obstructive pulmonary disease, Lancet, 389, pp. 1931-1940, (2017)
[2] Halpin D.M.G., Criner G.J., Papi A., Et al., Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease, Am J Respir Crit Care Med, 203, pp. 24-36, (2021)
[3] Vestbo J., Hurd S.S., Agusti A.G., Et al., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med, 187, pp. 347-365, (2013)
[4] Agusti A., Celli B.R., Criner G.J., Et al., Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary, Arch Bronconeumol, 59, pp. 232-248, (2023)
[5] Stolz D., Mkorombindo T., Schumann D.M., Et al., Towards the elimination of chronic obstructive pulmonary disease: A Lancet Commission, Lancet, 400, pp. 921-972, (2022)
[6] Celli B.R., Wedzicha J.A., Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease, N Engl J Med, 381, pp. 1257-1266, (2019)
[7] Agarwal D., COPD generates substantial cost for health systems, Lancet Glob Health, 11, pp. e1138-e1139, (2023)
[8] Kohansal R., Martinez-Camblor P., Agusti A., Et al., The Natural History of Chronic Airflow Obstruction Revisited, Am J Respir Crit Care Med, 180, pp. 3-10, (2009)
[9] Agusti A., Hogg J.C., Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease, N Engl J Med, 381, pp. 1248-1256, (2019)
[10] Vogelmeier C.F., Roman-Rodriguez M., Singh D., Et al., Goals of COPD treatment: Focus on symptoms and exacerbations, Respir Med, 166, (2020)

← 1 2 3 4 →